Article
Biotechnology & Applied Microbiology
Yixiu Yu, Jiamei Niu, Xingwei Zhang, Xue Wang, Hongquan Song, Yingqun Liu, Xiaohui Jiao, Fuyang Chen
Summary: This study identifies HOTAIRM1 as a significantly upregulated lncRNA in OSCC that is strongly associated with unfavorable prognosis. Bioinformatics analyses demonstrate that HOTAIRM1 is closely related to tumor stage, overall survival, genome instability, tumor cell stemness, tumor microenvironment, and immunocyte infiltration. Functional experiments confirm that HOTAIRM1 knockdown inhibits proliferation of OSCC cells and affects cell cycle regulation. In vivo experiments show that knocking down HOTAIRM1 inhibits tumor growth. Overall, HOTAIRM1 could serve as a potential prognostic biomarker and therapeutic target for OSCC.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Oncology
Yanjie Shuai, Yuansheng Duan, Mengqian Zhou, Kai Yue, Dandan Liu, Yan Fang, Yuxuan Wang, Yansheng Wu, Ze Zhang, Xudong Wang
Summary: The study developed a prognostic nomogram for patients with oral squamous cell carcinoma based on immunohistochemistry biomarkers, stratifying patients into high- and low-risk groups, and demonstrated its effectiveness through survival analysis.
Article
Dentistry, Oral Surgery & Medicine
Yi-Ju Tseng, Yi-Cheng Wang, Pei-Chun Hsueh, Chih-Ching Wu
Summary: A machine learning model using salivary autoantibody levels and demographic and behavioral data was successfully established to predict high-risk cases of oral cavity squamous cell carcinoma (OSCC). The model can be applied clinically through an online calculator to provide personalized information and reduce disease morbidity and mortality rates.
Article
Genetics & Heredity
Yijie Zhao, Dongyi Chen, Junhao Yin, Jian Xie, Chun-yu Sun, Mengmeng Lu
Summary: This study investigates the significance of tumor immune microenvironment (TIME) cells in oral squamous cell carcinoma (OSCC). A high TIME score is associated with better prognosis, overexpression of immunotherapy targets, and higher T-cell activity to inhibit tumor growth. The findings suggest that TIME score can serve as a prognostic biomarker and indicator for predicting immunotherapeutic outcomes in OSCC patients.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Diana Marzic, Blazen Marijic, Tamara Braut, Stefan Janik, Manuela Avirovic, Ita Hadzisejdic, Filip Tudor, Katarina Radobuljac, Miran Coklo, Boban M. Erovic
Summary: IMP3 expression is higher in malignant laryngeal lesions compared to dysplasia and benign lesions, serving as a useful marker to differentiate between invasive and noninvasive lesions. Higher IMP3 expression is associated with worse clinical outcomes in patients with squamous cell carcinoma of the larynx.
Article
Dentistry, Oral Surgery & Medicine
Hong Zhang, Zhenhua Wang, Zhongti Zhang
Summary: This study investigated the role and mechanism of a abnormally expressed circular RNA (hsa_circ_0009128) in oral squamous cell carcinoma (OSCC) progression. The results showed that hsa_circ_0009128 was upregulated in OSCC tissues and cell lines, and correlated with advanced TNM stage and lymph node metastasis. Knockdown of hsa_circ_0009128 inhibited cell proliferation and migration, and decreased EMT in OSCC cells. These findings suggest that hsa_circ_0009128 may play an important role in the malignant progression of OSCC by targeting MMP9 to activate EMT.
Article
Pharmacology & Pharmacy
Tiina Koivikko, Priscila Campioni Rodrigues, Mari Vehvilaeinen, Petra Hyvonen, Elias Sundquist, Riikka K. Arffman, Ahmed Al-Samadi, Hanna Valimaa, Tuula Salo, Maija Risteli
Summary: This study investigates the predominance of HSV-1 in oral HSV infections and its effect on oral tongue squamous cell carcinoma (OTSCC). The results show that HSV-1 is the predominant type in oral HSV infections and is also detected in OTSCC samples without clinical significance. Furthermore, low doses of HSV-1 do not affect cell survival or invasion in OTSCC.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Yinuan Zhao, Jiacheng Huang, Jianzhi Chen
Summary: This study identified significant differentially expressed genes in oral squamous cell carcinoma (OSCC) and constructed a prognostic model based on these genes. The results suggest that these genes may have value in prognostic evaluation for OSCC.
Review
Health Care Sciences & Services
Maria Menini, Emanuele De Giovanni, Francesco Bagnasco, Francesca Delucchi, Francesco Pera, Domenico Baldi, Paolo Pesce
Summary: Salivary miRNAs show potential as diagnostic and prognostic biomarkers for oral squamous cell carcinoma, providing a non-invasive and cost-effective method for diagnosis and aiding in monitoring disease progression and treatment response.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Ke Huang, Xiaoting Gu, Huimei Xu, Hui Li, Mingxuan Shi, Defang Wei, Shiqi Wang, Yao Li, Bin Liu, Yi Li
Summary: This study explored the link between necroptosis and oral squamous cell carcinoma (OSCC), and identified HPRT1 as a novel independent prognostic factor for OSCC. Knockdown of HPRT1 was found to inhibit tumor cell proliferation and migration. These findings contribute to the understanding of the mechanisms underlying OSCC and provide guidance for clinical diagnosis, targeted therapy, and prognosis evaluation.
Article
Biochemistry & Molecular Biology
Ramona Erber, Steffen Spoerl, Andreas Mamilos, Rosemarie Krupar, Arndt Hartmann, Matthias Ruebner, Juergen Taxis, Mareike Wittenberg, Torsten E. Reichert, Gerrit Spanier, Silvia Spoerl
Summary: The study found that in patients with oral squamous cell carcinoma (OSCC), a combined high central and low peripheral Trop-2 expression was associated with lower survival rates, while patients with lower central and/or higher peripheral Trop-2 expression had higher survival rates after five years.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biotechnology & Applied Microbiology
Mengxue Zhang, Xiao Chen, He Chen, Minyue Zhou, Yaoqiang Liu, Yali Hou, Minhai Nie, Xuqian Liu
Summary: The study identified 6 potential biomarkers for the diagnosis of oral squamous cell carcinoma (OSCC) using protein microarray assay, with GDF15 as a prognostic indicator. Experimental results showed significantly higher expression levels of these proteins in cancer cells compared to normal cells, and upregulated expression in cancer tissues.
Article
Dentistry, Oral Surgery & Medicine
Su-Wen Zhu, Shuo Wang, Zhi-Zhong Wu, Qi-Chao Yang, De-Run Chen, Shu-Cheng Wan, Zhi-Jun Sun
Summary: This study revealed the overexpression of CD168 in oral squamous cell carcinoma (OSCC) tissues, which was associated with worse patient survival and pathological grade. Additionally, CD168 expression was positively correlated with other marker expression in OSCC.
Article
Radiology, Nuclear Medicine & Medical Imaging
Russell Frood, Joseph Mercer, Peter Brown, Ane Appelt, Hitesh Mistry, Rohit Kochhar, Andrew Scarsbrook
Summary: The study aimed to develop and test predictive models for progression-free survival and overall survival in patients with anal squamous cell carcinoma. The results showed that a model based on patient age and metabolic tumor volume had good predictive potential for survival.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Irene H. Nauta, Danielle A. M. Heideman, Arjen Brink, Berdine van der Steen, Elisabeth Bloemena, Senada Koljenovic, Robert J. Baatenburg de Jong, C. Rene Leemans, Ruud H. Brakenhoff
Summary: The prevalence of HPV in oral cavity squamous cell carcinoma is low, and neither HPV status nor p16 status affects outcome, making it seem irrelevant for clinical management to determine HPV status in OCSCC.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Carina Strell, Axel Stenmark Tullberg, Reidunn Jetne Edelmann, Lars Andreas Akslen, Per Malmstrom, Marten Ferno, Erik Holmberg, Arne Ostman, Per Karlsson
Summary: The study found that a higher PDGFRb score is associated with a greater risk of any recurrence and may affect the efficacy of radiotherapy. However, while patients with high PDGFRb scores experienced reduced benefit from radiotherapy, no significant interaction was detected.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Slavica Janeva, Toshima Z. Parris, Salmir Nasic, Shahin De Lara, Karolina Larsson, Riccardo A. Audisio, Roger Olofsson Bagge, Aniko Kovacs
Summary: The comparison between STRAT4 and IHC/SISH showed discrepancies in BC patients, potentially resulting in more adjuvant treatment.
Article
Oncology
Carina Strell, Dick Folkvaljon, Erik Holmberg, Aglaia Schiza, Viktoria Thurfjell, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Warnberg, Arne Ostman
Summary: This study reveals the potential of stromal PDGFRb expression as a biomarker for RT benefit in DCIS patients, suggesting that low PDGFRb expression is predictive of strong RT benefit for IBE risk reduction, while high PDGFRb expression is not significantly associated with risk reduction.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Nina Oparina, Malin C. Erlandsson, Anna Faldt Beding, Toshima Parris, Khalil Helou, Per Karlsson, Zakaria Einbeigi, Maria I. Bokarewa
Summary: In this study, the activity of BIRC5 in breast cancer patients was explored for clinically relevant information, revealing that high levels of BIRC5 protein or mRNA were associated with poor survival, indicating its potential as a promising cancer survival marker. Different subsets by ER expression and nodal status supported an independent association of high BIRC5 with poor prognosis.
Article
Oncology
Jenny Nyqvist, Aniko Kovacs, Zakaria Einbeigi, Per Karlsson, Eva Forssell-Aronsson, Khalil Helou, Toshima Z. Parris
Summary: In breast cancer patients, the risk of developing other primary malignancies after treatment is relatively low, with more genetic alterations and similarities found in breast cancer compared to previously diagnosed primary malignancies (OPPM). While some patients showed consistent genetic alterations in both tumors, few recurrent genetic alterations were identified that could explain the development of multiple primary malignancies in the same patient.
Article
Oncology
Stefan Aebi, Per Karlsson, Irene L. Wapnir
Summary: Locally advanced breast cancer refers to breast adenocarcinoma that is inoperable without distant metastasis. A multidisciplinary approach is required for the treatment of patients with locally advanced breast cancer. Staging exams are necessary to assess the risk of distant metastasis. The incidence of locally advanced breast cancer has decreased in recent years. Treatment strategies for locally advanced breast cancer are often extrapolated from studies on patients with less or more advanced disease. Pathologic confirmation and molecular profiling are essential for determining the appropriate neoadjuvant chemotherapy. Preoperative endocrine therapy and targeted therapies are being investigated for certain clinical situations. Promising results have been observed with anti-HER2 agents in HER2 positive locally advanced breast cancer, and PD-1 and PD-L1 antibodies show potential in 'triple-negative' locally advanced breast cancer. Neoadjuvant therapy can lead to conservative surgery in many patients, but mastectomy may still be necessary for inflammatory breast cancer. Postoperative radiotherapy is usually recommended. Multidisciplinary teams play a crucial role in optimizing local control and preventing relapse. However, there is a need for specific research efforts to further improve the survival outcomes for patients with locally advanced breast cancer.
Article
Oncology
Julia Tutzauer, Martin Sjostrom, Erik Holmberg, Per Karlsson, Fredrika Killander, L. M. Fredrik Leeb-Lundberg, Per Malmstrom, Emma Nimeus, Marten Ferno, Annika Jogi
Summary: This study found that postoperative radiotherapy still benefits patients with hypoxic primary breast tumors. However, compared to patients with HIF-1 alpha-negative tumors, patients with HIF-1 alpha-positive tumors had a higher risk of recurrence and breast cancer death.
BRITISH JOURNAL OF CANCER
(2022)
Correction
Multidisciplinary Sciences
Malin Larsson, Nils Rudqvist, Johan Spetz, Emman Shubbar, Toshima Z. Parris, Britta Langen, Khalil Helou, Eva Forssell-Aronsson
Article
Multidisciplinary Sciences
Malin Larsson, Nils-Petter Rudqvist, Johan Spetz, Toshima Z. Parris, Britta Langen, Khalil Helou, Eva Forssell-Aronsson
Summary: This study aimed to compare the differences in RNA and protein expression in the thyroid and plasma of young and adult rats exposed to I-131 irradiation, and identify potential age-dependent biomarkers for I-131 exposure. The results showed distinct age-dependent differences in gene and protein expression, and novel biomarkers for thyroid I-131 exposure were identified.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Anna Faldt Beding, Peter Larsson, Khalil Helou, Zakaria Einbeigi, Toshima Z. Parris
Summary: Our study suggests that BIRC5 overexpression is associated with the initiation and progression of several cancer types, and therefore holds promise as a prognostic biomarker.
Article
Oncology
Aglaia Schiza, Viktoria Thurfjell, Axel Stenmark Tullberg, Helena Olofsson, Amanda Lindberg, Erik Holmberg, Troy Bremer, Patrick Micke, Per Karlsson, Fredrik Waernberg, Carina Strell
Summary: This study analyzed the clinical impact of tumor-infiltrating lymphocytes (TILs) in patients with ductal carcinoma in situ (DCIS). The results showed that high TILs were associated with an increased risk of ipsilateral breast events (IBEs) over five years post-surgery, particularly for HER2-negative DCIS patients. This indicates that TILs can serve as an important marker to determine the need for adjuvant therapy or potential benefits from immunotherapy in low-risk DCIS patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Moa Egelberg, Tommaso De Marchi, Gyula Pekar, Lena Tran, Par-Ola Bendahl, Axel Stenmark Tullberg, Erik Holmberg, Per Karlsson, Marianne Farnebo, Fredrika Killander, Emma Nimeus
Summary: The study evaluated the prognostic and predictive role of WRAP53 protein and RNA levels in breast cancer patients. Results showed that low WRAP53 protein levels were associated with increased risk of local recurrence and breast cancer-related death. Low WRAP53 RNA levels were associated with decreased effect of radiotherapy in relation to ipsilateral breast tumor recurrence, indicating potential radioresistance.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Axel Stenmark Tullberg, Martin Sjostrom, Lena Tran, Emma Nimeus, Fredrika Killander, Aniko Kovacs, Dan Lundstedt, Erik Holmberg, Per Karlsson
Summary: This study investigates the use of immunological biomarkers for individualized radiotherapy in breast cancer. The integration of histological grade, tumor-infiltrating lymphocytes (TILs), programmed cell death protein-1 (PD-1), and programmed death ligand-1 (PD-L1) can identify high-risk tumors with a reduced risk of recurrence after radiotherapy. However, no significant benefit of an activated immune infiltrate is observed in low-risk tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Medicine, Research & Experimental
Jacob M. van Laar, Alejhandra Lei, Mary Safy-Khan, Joachim Almquist, Graham Belfield, Karl Edman, Lisa Oeberg, Bastian R. Angermann, Inken Dillmann, Pia Berntsson, Damla Etal, Ian Dainty, Carol Astbury, Maria G. Belvisi, Szilard Nemes, Adam Platt, Susanne Prothon, Sara Samuelsson, Petter Svanberg, Christina Keen, SEMRA study grp
Summary: AZD9567, a selective nonsteroidal glucocorticoid receptor modulator, has similar efficacy and safety profile as prednisolone. In vitro studies showed that AZD9567 had similar anti-inflammatory response as prednisolone, but had no effect on the serum sodium:potassium ratio. Larger studies of longer duration are needed to determine if AZD9567 may be an alternative to prednisolone in treating inflammatory diseases.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2023)